US 12,083,113 B2
Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
Richard B. Silverman, Winnetka, IL (US); and Sun Yang, Lake Forest, CA (US)
Assigned to Northwestern University, Evanston, IL (US); and Chapman University, Orange, CA (US)
Filed by Northwestern University, Evanston, IL (US); and Chapman University, Orange, CA (US)
Filed on Sep. 12, 2022, as Appl. No. 17/942,928.
Application 17/942,928 is a continuation of application No. 16/703,009, filed on Dec. 4, 2019, granted, now 11,439,632.
Claims priority of provisional application 62/775,534, filed on Dec. 5, 2018.
Prior Publication US 2023/0017126 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/47 (2006.01); A61K 31/381 (2006.01); A61K 31/4164 (2006.01); A61K 31/495 (2006.01); A61K 38/21 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/47 (2013.01) [A61K 31/381 (2013.01); A61P 35/00 (2018.01); A61K 31/4164 (2013.01); A61K 31/495 (2013.01); A61K 38/212 (2013.01); C07K 16/2818 (2013.01)] 24 Claims
 
1. A method for administering immunotherapy to a subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of neuronal nitric oxide synthase (nNOS) for inducing an immunotherapeutic response in the subject,
wherein the subject has a disease or disorder characterized by elevated expression levels of programmed death-ligand 1 (PD-L1), and
wherein the inhibitor of nNOS is compound MAC-3-190 having a formula:

OG Complex Work Unit Chemistry
 or suitable pharmaceutical salts, solvates, or hydrates thereof, or compound HH044 having a formula:

OG Complex Work Unit Chemistry
 or suitable pharmaceutical salts, solvates, or hydrates thereof.